Lung Cancer Diagnostics Treatment Market Valued at $30.3 billion in 2025, Set to Grow at a 5.8% CAGR

Lung cancer diagnostics treatment market was valued at $30.3 billion in 2025 and is projected to reach $52.7 billion by 2035, growing at a CAGR of 5.8% during the forecast Period (2026-2035). The expansion of biomarker-driven therapies is evident, as regulatory approval of HER2-targeted treatments highlights the move towards precision oncology, which in turn fuels demand for advanced molecular and genomic diagnostics in lung cancer care. For instance, in February 2026, the FDA granted accelerated approval of zongertinib (Hernexeos) for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain-activating mutations, as part of the FDA's CNPV pilot program. The Beamion LUNG-1 trial involving 72 patients showed an objective response rate of 76%, with 64% of responders having a duration of response of at least 6 months. Warnings include hepatotoxicity, left ventricular dysfunction, interstitial lung disease/pneumonitis, and embryo-fetal toxicity. Recommended dosages are 120 mg daily for patients under 90 kg and 180 mg for those 90 kg or more, taken with or without food.

Browse the full report description of “Lung Cancer Diagnostics Treatment Market Size, Share & Trends Analysis by Type (Non?Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC)), By Diagnosis Type (Imaging Tests, Biopsy, and Molecular Testing), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By End-User (Hospitals, Diagnostic Laboratories, Specialty Clinics / Cancer Centers, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/lung-cancer-diagnostics-treatment-market

FDA Approves First HER2-Targeted Oral Therapy for Lung Cancer

• In November 2025, the FDA approved sevabertinib, the first cancer drug developed from research by Broad Institute scientists, in collaboration with Bayer. This oral treatment targets a type of non-small-cell lung cancer in adults with specific HER2 mutations who have prior chemotherapy or immunotherapy. Approved based on a Bayer clinical trial showing over 70% of patients had tumor shrinkage, the drug signifies a pivotal achievement in translating academic research into effective medical treatments, benefiting approximately 4,000 to 8,000 lung cancer patients annually, particularly among women.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Diagnosis Type
  • By Treatment Type
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AstraZeneca PLC, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Pfizer Inc., among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lung Cancer Diagnostics Treatment Market Report Segment

By Type

• Non?Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

By Diagnosis Type

• Imaging Tests
• Biopsy
• Molecular Testing

By Treatment Type

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

By End?User

• Hospitals
• Diagnostic Laboratories
• Specialty Clinics / Cancer Centers
• Others

Global Lung Cancer Diagnostics Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lung-cancer-diagnostics-treatment-market